This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bernardo, M. E. Articles by Locatelli, F. Search for Related Content PubMed PubMed Citation Articles by Bernardo, M. E. Articles by Locatelli, F.

Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term In vitro Culture and Do Not Exhibit Telomere Maintenance Mechanisms

¹ Oncoematologia Pediatrica and ² Biologia Generale e Genetica Medica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Università di Pavia, Pavia, Italy; and ³ Dipartimento di Oncologia Sperimentale, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy

Requests for reprints: Maria Ester Bernardo, Oncoematologia Pediatrica, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Università di Pavia, P.le Golgi 2, 27100 Pavia, Italy. Phone: 39-0382-502607; Fax: 39-0382-501251; E-mail: mebernardo{at}gmail.com.

Significant improvement in the understanding of mesenchymal stem cell (MSC) biology has opened the way to their clinical use. However, concerns regarding the possibility that MSCs undergo malignant transformation have been raised. We investigated the susceptibility to transformation of human bone marrow (BM)–derived MSCs at different in vitro culture time points. MSCs were isolated from BM of 10 healthy donors and propagated in vitro until reaching either senescence or passage (P) 25. MSCs in the senescence phase were closely monitored for 8 to 12 weeks before interrupting the cultures. The genetic characterization of MSCs was investigated through array-comparative genomic hybridization (array-CGH), conventional karyotyping, and subtelomeric fluorescent in situ hybridization analysis both before and after prolonged culture. MSCs were tested for the expression of telomerase activity, human telomerase reverse transcriptase (hTERT) transcripts, and alternative lengthening of telomere (ALT) mechanism at different passages. A huge variability in terms of proliferative capacity and MSCs life span was noted between donors. In eight of 10 donors, MSCs displayed a progressive decrease in proliferative capacity until reaching senescence. In the remaining two MSC samples, the cultures were interrupted at P25 to pursue data analysis. Array-CGH and cytogenetic analyses showed that MSCs expanded in vitro did not show chromosomal abnormalities. Telomerase activity and hTERT transcripts were not expressed in any of the examined cultures and telomeres shortened during the culture period. ALT was not evidenced in the MSCs tested. BM-derived MSCs can be safely expanded in vitro and are not susceptible to malignant transformation, thus rendering these cells suitable for cell therapy approaches. [Cancer Res 2007;67(19):9142–9]

This article has been cited by other articles:

				M. E.J. Reinders, W. E. Fibbe, and T. J. Rabelink Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation Nephrol. Dial. Transplant., October 26, 2009; (2009) gfp552v1. [Abstract] [Full Text] [PDF]

				G. Piaggio, V. Rosti, M. Corselli, F. Bertolotti, G. Bergamaschi, S. Pozzi, D. Imperiale, B. Chiavarina, E. Bonetti, F. Novara, et al. Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker Blood, October 1, 2009; 114(14): 3127 - 3130. [Abstract] [Full Text] [PDF]

				G. V. Rosland, A. Svendsen, A. Torsvik, E. Sobala, E. McCormack, H. Immervoll, J. Mysliwietz, J.-C. Tonn, R. Goldbrunner, P. E. Lonning, et al. Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation Cancer Res., July 1, 2009; 69(13): 5331 - 5339. [Abstract] [Full Text] [PDF]

				S. S. Fazel, D. Angoulvant, J. Butany, R. D. Weisel, and R.-K. Li Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1388 - 1389. [Full Text] [PDF]

				I. B. Copland, E. M. Jolicoeur, M.-A. Gillis, J. Cuerquis, N. Eliopoulos, B. Annabi, A. Calderone, J.-F. Tanguay, A. Ducharme, and J. Galipeau Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties Cardiovasc Res, August 1, 2008; 79(3): 405 - 415. [Abstract] [Full Text] [PDF]

				D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667. [Full Text] [PDF]

				B. Janic, A. S. Arbab, R. Schafer, R. Kehlbach, and J. Wiskirchen Iron Oxide-Transfection Agent Complexes Are Not Expected to Coat the Cell Membrane and Prevent CD71 Expression Radiology, June 1, 2008; 247(3): 914 - 915. [Full Text] [PDF]